Propofol-Related Infusion Syndrome (PRIS) is primarily caused by:

Prepare for the Critical Care Air Transport Team (CCATT) Test. Dive into interactive quizzes and detailed flashcards. Each question provides hints and in-depth explanations. Master the material and ace your exam!

Multiple Choice

Propofol-Related Infusion Syndrome (PRIS) is primarily caused by:

Propofol-Related Infusion Syndrome (PRIS) is primarily associated with high doses of propofol administered over prolonged periods of time. The risk of developing PRIS increases significantly when propofol is used at high doses, typically considered to be greater than 4 mg/kg/hour, and especially when it is infused continuously for more than 48 hours. This syndrome is characterized by a range of serious complications, including metabolic acidosis, rhabdomyolysis, cardiac failure, and renal failure. The prolonged exposure to elevated levels of propofol can lead to alteration in the body’s metabolism, especially in critically ill patients who may already have compromised organ function. In contrast, low doses for short durations do not generally pose the same risk for developing PRIS. The combination with other sedatives does not have a direct causal link to PRIS either, as it is the characteristics of propofol itself when used inappropriately that primarily drive the syndrome. Rapid infusion rates can also contribute to side effects, but it is the dosage and duration of exposure that carry the most substantial risk for PRIS.

Propofol-Related Infusion Syndrome (PRIS) is primarily associated with high doses of propofol administered over prolonged periods of time. The risk of developing PRIS increases significantly when propofol is used at high doses, typically considered to be greater than 4 mg/kg/hour, and especially when it is infused continuously for more than 48 hours.

This syndrome is characterized by a range of serious complications, including metabolic acidosis, rhabdomyolysis, cardiac failure, and renal failure. The prolonged exposure to elevated levels of propofol can lead to alteration in the body’s metabolism, especially in critically ill patients who may already have compromised organ function.

In contrast, low doses for short durations do not generally pose the same risk for developing PRIS. The combination with other sedatives does not have a direct causal link to PRIS either, as it is the characteristics of propofol itself when used inappropriately that primarily drive the syndrome. Rapid infusion rates can also contribute to side effects, but it is the dosage and duration of exposure that carry the most substantial risk for PRIS.

More practice questions